SCHEMBL6079913

SCHEMBL6079913

Cc1ccc(S(=O)(=O)Nc2c(C)c(C(=O)O)nc3c(O)cccc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HKDC1 Q2TB90 1/20 0.51
TDP1 Q9NUW8 5/20 0.48
GAA P10253 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HTT P42858 2/20 0.48
NPC1 O15118 2/20 0.48
KDM4E B2RXH2 1/20 0.48
GFER P55789 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KMT2A Q03164 6/20 0.46
MEN1 O00255 5/20 0.46
PKM P14618 1/20 0.46
EP300 Q09472 1/20 0.46
KAT2B Q92831 1/20 0.46
KAT8 Q9H7Z6 1/20 0.46
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
G6PD P11413 1/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080620 0.87 HKDC1 (0.44) HKDC1TDP1GAAALDH1A1HTT
SCHEMBL6080095 0.80 AR (0.48) HKDC1ALDH1A1NPC1KDM4ESMN1; SMN2
SCHEMBL6079844 0.78 TDP1 (0.56) HKDC1TDP1GAAALDH1A1HTT
SCHEMBL6080384 0.74 KDM4E (0.46) GAAALDH1A1KDM4ESMN1; SMN2KMT2A
SCHEMBL6079908 0.72 TDP1 (0.54) HKDC1TDP1GAAALDH1A1HTT
SCHEMBL6080749 0.72 CYP1A2 (0.54) ALDH1A1KDM4EKMT2AG6PDRAB9A
SCHEMBL13485888 0.70 KDM4E (0.63) HKDC1TDP1GAAALDH1A1HTT
SCHEMBL5307424 0.69 EP300 (0.83) HKDC1TDP1GAAALDH1A1HTT
SCHEMBL7572310 0.69 ALDH1A1 (0.66) HKDC1TDP1GAAALDH1A1HTT
SCHEMBL7176595 0.69 ALDH1A1 (0.66) TDP1GAAALDH1A1HTTGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL HKDC1 2305/4885TDP1 2264/4885GAA 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.